{"organizations": [], "uuid": "061e231d495aa0930d3f0e0b323a0b9e7dc94676", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ziopharm-oncology-addresses-rumors/brief-ziopharm-oncology-addresses-rumors-and-stock-volatility-affirms-2018-guidance-idUSASB0C48H", "country": "US", "domain_rank": 408, "title": "BRIEF-Ziopharm Oncology Addresses Rumors And Stock Volatility, Affirms 2018 Guidance", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-06T18:05:00.000+02:00", "replies_count": 0, "uuid": "061e231d495aa0930d3f0e0b323a0b9e7dc94676"}, "author": "", "url": "https://www.reuters.com/article/brief-ziopharm-oncology-addresses-rumors/brief-ziopharm-oncology-addresses-rumors-and-stock-volatility-affirms-2018-guidance-idUSASB0C48H", "ord_in_thread": 0, "title": "BRIEF-Ziopharm Oncology Addresses Rumors And Stock Volatility, Affirms 2018 Guidance", "locations": [], "entities": {"persons": [], "locations": [{"name": "co", "sentiment": "none"}], "organizations": [{"name": "ziopharm oncology inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "reuters staff  feb", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 06 PM / in 9 minutes BRIEF-Ziopharm Oncology Addresses Rumors And Stock Volatility, Affirms 2018 Guidance Reuters Staff \nFeb 6 (Reuters) - Ziopharm Oncology Inc: \n* ZIOPHARM ONCOLOGY ADDRESSES RUMORS AND STOCK VOLATILITY, AFFIRMS 2018 GUIDANCE \n* COMPANY REAFFIRMS ITS GUIDANCE FOR ALL ACTIVITIES IN 2018 \n* ZIOPHARM HAS HAD NO DISCUSSIONS AND HAS NO PLANS TO UNDERTAKE AN UNDERWRITTEN STOCK OFFERING AT THIS TIME​ \n* AS OF DEC. 31, 2017, CO HAD $70.9 MILLION OF CASH RESOURCES & $34.6 MILLION FROM PRE-PAYMENT FOR PROGRAMS TO BE CONDUCTED BY CO \n* CURRENT RESOURCES WILL BE SUFFICIENT TO FUND ITS CURRENTLY PLANNED OPERATIONS INTO Q4 OF 2018​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-06T18:05:00.000+02:00", "crawled": "2018-02-06T18:22:16.000+02:00", "highlightTitle": ""}